Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ATMP Firms Call For Streamlined EU Trial Approvals To Boost Competitiveness

Bluebird Bio & ARM Are Cautiously Optimistic Of Change

Executive Summary

Gene therapy developer bluebird bio and the Alliance for Regenerative Medicine say that Europe is losing its edge in advanced therapy clinical trials. But they believe that recommendations made in a new report from ARM could help kickstart moves to streamline trial approvals for cell and gene therapies. 

You may also be interested in...



2019 Sees Decline In EMA Drug Approval Recommendations

The number of positive opinions given by the EMA’s CHMP has fallen to 66 this year from 84 in 2018.

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

EU Ministers Want Decisive Action On Medicines Access & Shortages

Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.

Topics

UsernamePublicRestriction

Register

PS141127

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel